Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
Cytokinetics, incorporated (NASDAQ: CYTK) reported a net loss of $39.4 million, or $0.66 per share for Q1 2020, compared to a loss of $29.4 million, or $0.54 per share in Q1 2019. Cash, cash equivalents, and investments stand at $237.2 million, providing a runway of over two years based on expected spending of $105-115 million in 2020. The company anticipates top-line results from the GALACTIC-HF trial in Q4 2020 and continues to prioritize clinical programs despite COVID-19 related challenges.